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ABSTRACT
Introduction: Psoriasis affecting the head and
neck can be difficult to treat, and the presence
of extensive and highly visible lesions may
result in substantial psychosocial burdens.
Secukinumab, a monoclonal antibody that
selectively targets interleukin-17A, provides
rapid and sustained clearance of
moderate-to-severe psoriasis. The objective of
this study was to evaluate the efficacy of
secukinumab on moderate-to-severe psoriasis
affecting the head and neck. The safety and
overall efficacy of secukinumab in patients with
moderate-to-severe psoriasis will be described.
Methods: Data were pooled from four phase 3
studies. To be included in the head and neck
analysis, patients were required to have Baseline
head and neck Psoriasis Severity Area Index
(PASI) scores C12 and psoriasis covering C10%
of the head and neck. Secukinumab (300 or
150 mg) was administered at Baseline, Weeks 1,
2 and 3, and then every 4 weeks from Week 4 to
48.
Results: Secukinumab demonstrated high
efficacy on the head and neck and the
whole body. At Week 52, head and neck PASI
90/100 subscore responses were achieved
by 76.0%/68.7% of patients receiving
secukinumab 300 mg, respectively, and
by 61.4%/53.1% of patients receiving
secukinumab 150 mg, respectively. At Week 52,
whole body composite PASI 90/100
responses were achieved by 68.1%/40.8% of
patients receiving secukinumab 300 mg,
respectively, and by 47.6%/24.3% of patients
receiving secukinumab 150 mg, respectively.
Secukinumab also improved Dermatology Life
Quality Index scores.
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INTRODUCTION
The head (including the scalp and face) and
neck are the body areas most commonly
affected by psoriasis, and, in many cases, the
most difficult areas to treat [1–3]. Scalp psoriasis
is estimated to affect between 40% and 90% of
individuals with psoriasis, and facial psoriasis
has been reported by 17–29% of adults with
psoriasis [2, 4]. In addition to physical
symptoms of itching, pain, lesion cracking,
and bleeding that may cause discomfort and
reduced quality of life, individuals with
extensive and highly visible psoriasis affecting
areas such as the head and neck can experience
higher psychological burdens [2, 5, 6].
Symptoms of psoriasis can cause patients to
face social stigmatization that results in
embarrassment, shame, and stress [7]. Visible
psoriasis can also negatively affect work or
school attendance and performance, reduce
self-confidence, and interfere with daily
routines [2, 8].
The disease burden in patients with head and
neck psoriasis is substantial. Patients with facial
psoriasis have significantly greater whole body
Psoriasis Severity Area Index (PASI) scores than
patients without facial involvement (15.6 vs.
6.9; P\0.05) and facial psoriasis is associated
with longer disease duration and younger age of
onset [9, 10]. Quality of life is more negatively
impacted in women with scalp psoriasis, and
many individuals with scalp psoriasis report
being inconvenienced by caring for their scalp
[11, 12]. Additionally, scalp psoriasis has been
shown to impair physical and psychological
health regardless of the severity of psoriasis on
other body regions [13].
Secukinumab is a human monoclonal
antibody that selectively binds to and
neutralizes interleukin (IL)-17A, a key cytokine
in the pathogenesis of psoriasis [14]. The safety
and efficacy of secukinumab has previously
been demonstrated in phase 3 studies of
patients with moderate-to-severe plaque
psoriasis [15–18]. In this report, 52-Week
results were pooled from four phase 3 studies
of secukinumab in patients with
moderate-to-severe psoriasis, and efficacy was
evaluated for (1) head and neck (HN)PASI
subscores and (2) whole body composite PASI
scores. Subcomponent PASI results for the
trunk, upper limbs, and lower limbs are
reported separately in this publication by
Menter et al. [19].
METHODS
Study Design
Data were pooled from four randomized,
double-blind, placebo-controlled, parallel-group
phase 3 trials [efficacy of response and safety of
two fixed secukinumab regimens in psoriasis
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(ERASURE, ClinicalTrials.gov identifier,
NCT01365455), full year investigative
examination of secukinumab vs. etanercept
using two dosing regimens to determine efficacy
in psoriasis (FIXTURE, ClinicalTrials.gov
identifier, NCT01358578), first study of
secukinumab in pre-filled syringes in subjects
with chronic plaque-type psoriasis (FEATURE,
ClinicalTrials.gov identifier, NCT01555125), and
judging the efficacy of secukinumab in patients
with psoriasis using autoinjector (JUNCTURE,
ClinicalTrials.gov identifier, NCT01636687)].
The design of these trials has been previously
reported in detail [15–17]. Briefly, secukinumab or
placebo was administered at Baseline, Weeks 1, 2
and 3, and then every 4 weeks fromWeek 4 to 48.
At Week 12, patients receiving placebo were
randomized to secukinumab. Secukinumab was
administered by subcutaneous injection; in
ERASURE and FIXTURE the lyophilisate in vial
formulation was used, in FEATURE a prefilled
syringe was used, and in JUNCTURE an
autoinjector was used.
Study Population
Male and female patients (C18 years of age) with
moderate-to-severe plaque psoriasis of
C6months’ duration that was poorly controlled
by topical treatments, phototherapy, and/or
previous systemic therapy were considered
eligible for the study population.
Moderate-to-severe plaque psoriasis was defined
as Baseline PASI score C12, Investigator’s Global
Assessment modified 2011 (IGA mod 2011) [20]
score C3, and total body surface area (BSA)
affected C10%. Exclusion criteria included
active, ongoing inflammatory diseases; active,
ongoing, chronic or recurrent infectious disease,
or evidence of active tuberculosis infection;
or underlying condition significantly
immunocompromising the patient and/or
placing the patient at unacceptable risk for
receiving an immunomodulatory therapy (e.g.,
lymphoproliferative disease, malignancy, history
of malignancy within the past 5 years; past
medical history of HIV, hepatitis B, or hepatitis
C). To be included in the head and neck
subanalysis, patients had to have a PASI score
C12 for the head and neck region and have
psoriasis covering C10% of the BSA of the head
and neck region. Composite PASI scores are
calculated as a weighted average of PASI scores
for the head and neck, upper limbs, trunk, and
lower limbs using multipliers of 0.1, 0.2, 0.3, and
0.4, respectively, to account for the relative
percentage of total BSA these regions make up.
Scores for each body region are calculated as the
affected area (A) score multiplied by the sum of
erythema (E), induration (I), and desquamation
(D) scores for that body region.
Efficacy and Safety Assessments
Co-primary efficacy variables in all four trials
were PASI 75 response rates and IGA mod 2011
0/1 response rates at Week 12. PASI 90 response
rate at Week 12 was a key secondary endpoint in
all trials. PASI 100 response rates at Week 12 and
achievement of dermatology life quality index
(DLQI) [21] scores of 0/1, representing little or
no effect of psoriasis on patient quality of life,
were also measured. Safety and tolerability
assessments included vital signs, clinical
laboratory variables, electrocardiograms, and
adverse event (AE) monitoring. Week 52 safety
data were pooled from all 4 studies.
Statistical Analysis
Data from ERASURE, FIXTURE, FEATURE, and
JUNCTURE were pooled to assess long-term
efficacy through Week 52. Missing values were
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imputed by multiple imputation (MI), in which
missing data are replaced by values derived from
large data sets of possible values. The SAS
(version 9.3, SAS Institute, Cary, NC, USA) MI
procedure was used to generate data sets for 500
imputations. Results are presented by MI
because this method more accurately reflects
response rates observed in a clinical setting than
the more conservative non-responder
imputation method, which underestimates
PASI responses [22]. Efficacy results are
presented for the full analysis set of patients,
which is defined as all patients to whom study
treatment had been assigned. Safety results are
presented for the safety set of patients, which is
defined as all patients who took at least one
dose of study treatment during the treatment
period and who had at least one Post-Baseline
safety assessment. This article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Patient Demographics
Treatment groups were well balanced for
demographic and Baseline disease
characteristics in the overall study population
(Table 1). Baseline disease characteristics were
representative of the target population with
moderate-to-severe plaque psoriasis. The mean
age of patients at Baseline was 45 years, and
approximately 70% of participants were White
men. Patients had a mean body weight of
approximately 86 kg and a mean body mass
index of approximately 29 kg/m2. Disease
severity was comparable across treatment
groups. Mean PASI scores at Baseline were 22.7
for patients receiving secukinumab 300 mg,
22.8 for patients receiving secukinumab
150 mg, and 22.5 for patients receiving placebo.
Head and Neck Efficacy
Treatment with secukinumab 300 mg and
secukinumab 150 mg resulted in rapid and
sustained skin clearance on the head and
neck. For secukinumab 300 mg, initial HNPASI
75, 90, and 100 response rates were maintained
to Week 52. At Week 16, 82.4% and 72.2% of
patients receiving secukinumab 300 mg had
HNPASI 90 and HNPASI 100 responses,
respectively. At Week 52, HNPASI 90 and
HNPASI 100 response rates were achieved by
76.0% and 68.7%, respectively, of patients
receiving secukinumab 300 mg. With
secukinumab 150 mg, HNPASI 90 and 100
response rates were achieved by 69.9% and
57.7% of patients at Week 16, respectively and
by 61.4% and 53.1% of patients at Week 52,
respectively (Fig. 1). A 50% reduction in mean
HNPASI score occurred after 2.0 weeks (95%
confidence interval [CI] 1.9, 2.2) with
secukinumab 300 mg and after 2.7 weeks (95%
CI 2.6, 2.9) with secukinumab 150 mg (Fig. 2).
Whole Body Efficacy
Pooled efficacy responses through Week 52
from these four phase 3 trials are presented in
Fig. 3. In the overall pooled study population,
secukinumab provided rapid skin clearance
with responses being observed as early as
Week 1. Initial responses were maintained to
Week 52 and the greatest benefit was observed
with secukinumab 300 mg. At Week 52, PASI 90
and PASI 100 were achieved by 68.1% and
40.8% of patients receiving secukinumab
300 mg, respectively, and by 47.6% and 24.3%
of patients receiving secukinumab 150 mg,
respectively.
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Gender (male), n (%) 477 (69.0) 485 (70.1) 484 (69.9)
Age (years), mean (SD) 44.9 (13.3) 45.1 (13.4) 44.7 (12.8)
Range 18–83 18–83 18–82
Race, n (%)
White 505 (73.1) 499 (72.1) 509 (73.6)
Asian 129 (18.7) 129 (18.6) 121 (17.5)
Black 9 (1.3) 13 (1.9) 13 (1.9)
Other 48 (6.9) 51 (7.4) 49 (7.1)
Height (cm), mean (SD)a 171.2 (9.6) 171.3 (10.2) 171.6 (10.2)
Range 145.0–198.5 145.0–197.0 141.0–200.7
Weight (kg), mean (SD) 86.6 (23.2) 86.6 (23.2) 86.0 (22.6)
Range 45.0–219.1 43.1–215.0 42.0–191.9
BMI (kg/m2), mean (SD)a 29.4 (6.9) 29.4 (7.0) 29.1 (6.9)
Range 17.4–67.4 16.5–79.7 16.2–71.2
PASI score, mean (SD) 22.7 (9.4) 22.8 (10.0) 22.5 (9.7)
Range 11.2–72.0 12.0–69.6 10.6–72.0
IGA modiﬁed 2011 score, n (%)
3 (Moderate disease) 436 (63.1) 439 (63.4) 424 (61.3)
4 (Severe disease) 255 (36.9) 253 (36.6) 268 (38.7)
Time since ﬁrst psoriasis diagnosis (y), mean (SD) 17.0 (12.0) 17.9 (12.5) 17.5 (12.2)
Range 0.5–61.5 0.5–69.0 0.5–68.1
Previous exposure to systemic psoriasis therapyb
(yes), n (%)
438 (63.4) 447 (64.6) 420 (60.7)
Previous exposure to biologic systemic psoriasis
therapyb (yes), n (%)
146 (21.1) 161 (23.3) 147 (21.2)
Previous exposure to non-biologic systemic psoriasis
therapyb (yes), n (%)
373 (54.0) 393 (56.8) 363 (52.5)
Results are for the full analysis set of patients
BMI body mass index, BSA body surface area, IGA investigator’s global assessment, PASI psoriasis area and severity index,
SD standard deviation
a n = 688 for secukinumab 300 mg, n = 692 for secukinumab 150 mg
b n = 690 for secukinumab 300 mg
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Treatment with secukinumab also showed
rapid and significant improvement in quality of
life asmeasured byDLQI. AtWeek 12, DLQI scores
of 0 or 1 were achieved by 58.8% of patients
receiving secukinumab 300 mg and 50.1% of
patients receiving secukinumab 150mg.
Improvements in DLQI continued to Week 52
with DLQI scores of 0 or 1 being achieved by
67.9% and 53.7% of patients receiving
secukinumab 300 mg and secukinumab 150mg,
respectively. Mean decreases (improvements) in
DLQI from Baseline to Week 52 were -11.0 with
secukinumab 300mg and -9.2 with
secukinumab 150 mg, and these responses
surpassed the C5-point reduction in DLQI
required for a minimal clinically important
difference in patients with psoriasis that are
receiving biologic therapy [23].
Safety
Secukinumab demonstrated a favorable safety
profile in the overall pooled study population,
and the rates of AEs were similar between the
300 and 150 mg doses (Table 2). Through Week
52, AEs were reported in 83.3% of patients
receiving secukinumab 300 mg and in 81.2% of
patients receiving secukinumab 150 mg. The
most common AEs for both secukinumab doses
were nasopharyngitis (23.7–24.9%), headache
(9.4–11.4%), diarrhea (6.5–7.8%), and upper
respiratory tract infection (7.7–9.2%). Serious
Fig. 1 Efﬁcacy of secukinumab on the head and neck over
time. Missing values were imputed by multiple imputation.
Clinical response rates for a HNPASI 75, b HNPASI 90,
and c HNPASI 100 from Baseline to Week 52.
n represents the number of evaluable subjects. HNPASI
75/90/100, 75%/90%/100% improvement from Baseline
head and neck psoriasis area and severity index scores
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Fig. 2 Percent change in mean HNPASI score over time.
A repeated-measure, mixed-effects model was used to
analyze the mean percent change from Baseline in PASI
score. The median time to a 50% reduction in mean
HNPASI score was estimated from parametric bootstrap
samples with the use of linear interpolation between time
points. CI conﬁdence interval, HNPASI head and neck
psoriasis area severity index
Fig. 3 Efﬁcacy of secukinumab on the whole body over
time. Missing values were imputed by multiple imputation.
Clinical response rates for a PASI 75, b PASI 90, and
c PASI 100 from Baseline to Week 52. PASI 75/90/100,
75%/90%/100% improvement from Baseline psoriasis area
and severity index scores
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AEs were reported in 7.0% of patients receiving
secukinumab 300 mg and in 6.9% of patients
receiving secukinumab 150 mg. Discontinuation
of secukinumab due to AEs occurred in 3.0% of
patients receiving secukinumab 300 mg and in
3.6% of patients receiving secukinumab 150 mg.
DISCUSSION
The efficacy of secukinumab 300 mg and
secukinumab 150 mg was previously
demonstrated to be superior to placebo (in
ERASURE, FIXTURE, FEATURE, and
JUNCTURE) and etanercept (in FIXTURE) at
Week 12 [15–17]. Results from this pooled
analysis of four phase 3 trials show that
secukinumab is effective for the treatment of
moderate-to-severe psoriasis affecting the head
and neck, and the whole body. Secukinumab
therapy resulted in rapid improvement of
psoriasis on the head and neck. Improvements
were observed as early as Week 1 at which point
secukinumab 300 mg provided an approximate
25% reduction in mean HNPASI score from
Baseline. Disease clearance continued to
increase on the head and neck after the first
Week, and patients experienced a 50%
reduction in mean HNPASI score after
2.0 weeks of treatment with secukinumab
300 mg. Improvement in psoriasis affecting
the head and neck were maintained through
Week 52, with the greatest benefit seen in
patients receiving secukinumab 300 mg (Fig. 1).
The efficacy and safety of secukinumab was
consistent across all four phase 3 trials that were
pooled for this analysis. Results from this study
are also consistent with findings from other
studies that evaluated the efficacy of biologic
Table 2 Summary of adverse events







Discontinuation due to adverse
event
21 (3.0) 25 (3.6) 9 (1.3)
Any serious adverse event 48 (7.0) 48 (6.9) 12 (1.7)
Any adverse event 575 (83.3) 562 (81.2) 340 (49.0)
Most common adverse events ([5%)
Nasopharyngitis 172 (24.9) 164 (23.7) 60 (8.6)
Headache 79 (11.4) 65 (9.4) 36 (5.2)
Diarrhea 54 (7.8) 45 (6.5) 10 (1.4)
Upper respiratory tract infection 53 (7.7) 64 (9.2) 5 (0.7)
Cough 45 (6.5) 21 (3.0) 9 (1.3)
Back pain 37 (5.4) 30 (4.3) 10 (1.4)
Hypertension 35 (5.1) 37 (5.3) 12 (1.7)
Arthralgia 34 (4.9) 38 (5.5) 17 (2.4)
Results are for the safety set of patients. Safety results are only presented to Week 12 for placebo because at Week 12,
patients receiving placebo were randomized to secukinumab
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agents by body region [24–26]. In these studies,
along with the findings reported here, head and
neck plaque psoriasis generally responded
favorably, rapidly, and significantly to biologic
treatment. Conversely, psoriasis on the head and
neck does not typically respond well to
conventional systemic therapies, and topical
therapies can be burdensome to apply resulting
in low adherence [26, 27]. This study was limited
by the inability to differentiate between affected
areas of the head and neck (e.g., scalp vs face
psoriasis) because PASI does not allow for
differentiation of specific regions of the head
and neck. A study is currently ongoing that will
evaluate the efficacy of secukinumab on scalp
psoriasis, and results from this trial will provide
further data on the treatment of this difficult to
manage area [28]. Additionally, there was no
control group after Week 12.
Resultsof thispooledanalysisdemonstrate that
secukinumab is an effective and well-tolerated
treatment for plaque psoriasis of the head and
neck. The majority of the patients treated with
secukinumab 300 mg achieved almost clear or
clear skin as indicated by high HNPASI 90 and
HNPASI 100 response rates. Secukinumab also
provided robust overall efficacy. AtWeek 12, PASI
75 response rates were similar between the head
and neck region and the whole body. A larger
proportion of patients receiving secukinumab
300 mg achieved HNPASI 90 and HNPASI 100
(73.3% and 61.1%, respectively) response rates at
Week 12 than achieved composite PASI 90 and
PASI100 (59.6%and29.0%, respectively) response
rates over the same time period. These findings
indicate that patients achieve complete or almost
complete clearance of psoriasis on the head and
neck at a quicker rate than on the whole body
following treatment with secukinumab. Likewise,
at Week 52, HNPASI response rates were
numerically greater than composite PASI
response rates. With secukinumab 300 mg,
HNPASI 90 and HNPASI 100 responses were
achieved by 76.0% and 68.7% of patients,
respectively, compared with composite PASI 90
and PASI 100 response rates of 68.1% and 40.8%,
respectively. It is important to note that
achievement of a PASI 100 response for a
particular body region is easier than achievement
of the same response for the whole body because
full clearance across all body regions is not
required. The rapid and sustained clearance of
psoriasis from the head and neck with
secukinumab may provide patients with a
meaningful improvement in areas of the body
that are associated with a large psychosocial
burden.
In the overall pooled analysis population,
disease clearance was associated with
improvement in quality of life for patients
receiving secukinumab. In ERASURE and
FIXTURE, findings from the Psoriasis Symptom
Diary indicate that improvements in PASI
response rates are paralleled by significant
reductions in patient-reported symptoms of
itching, pain, and scaling [29]. Additionally,
improvements in DLQI at Week 52 with
secukinumab were sufficient to meet the
definition of a clinically important difference
in health-related quality of life for patients with
psoriasis who are receiving biologic therapy
[23]. The importance of such improvement in
DLQI should be highlighted because it is an
indicator of patient satisfaction with therapy
and likely leads to stronger adherence and
better clinical outcomes.
CONCLUSION
Pooled results of four phase 3 studies of
secukinumab showed robust and sustained
efficacy in treating psoriasis affecting both the
head and neck and the whole body.
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